Pricing Log in Create free account
Friday 6 November 2026 Export MD’s income statement to Excel — free account

Pediatrix Medical Group, Inc.

MD Healthcare Medical Care Facilities

Pediatrix Medical Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 4.92% from fiscal 2024.

Revenue
+1.72%
EPS
−27.6%
Free cash flow
−14.4%
Total debt
−4.11%

Quarter to September 2026, against a year earlier

31.73 1.07 −3.26%
Market cap
$2.5B
P/E
17.1×
Fwd P/E
15.3×
Dividend yield
—
F-score
7/9
Altman Z
2.05
Beneish M
−2.86
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 1.37
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 1 — — — — 1 — — — — — —
Insider Ownership 0.51%

Capital & Financial Ratios $m

Size
Market Cap 2,490.00
Revenue ttm 1,959.12
Net income ttm 150.09
Free cash flow ttm 209.59
Net debt Q 151.88
Valuation
P/E 17.08
Forward P/E 15.30
Price / sales 1.25
Forward P/S Powerpack
Price / FCF 11.70
Price / book 2.89
Financial health
Current ratio Q 1.28
Debt / equity Q 0.68
Interest coverage Q 8.02
Growth
Revenue growth Q +1.72% (above 0%: growing)
Operating income growth Q −4.17% (below 0%: shrinking)
EPS, this year +17.89% (at or above 15%: strong)
EPS, next year A +3.18%
Revenue, next year A +2.78%
EPS, past 5 yrs —
EPS, next 5 yrs A +8.02%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.3×, against a ten-year median of 1.5×; over the ten years it ranged from 0.6× in 2024 to 3.9× in 2019.
P/E against its own 10 years 61.75%
10-year low 10-year high
P/S against its own 10 years 62.52%
10-year low 10-year high
P/B against its own 10 years 94.39%
10-year low 10-year high
EV/Sales against its own 10 years 42.72%
10-year low 10-year high
EV/FCF against its own 10 years 40.37%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 178 349 500 426
Receivables 280 273 242 240
Inventory — — — —
Other 12 5 9 9
483 640 764 684
2023 2024 2025 Q'26
Payables 351 399 420 343
ST’ Debt 15 21 27 180
Other — — — —
389 434 459 536

Compound Annual Growth %

10y 5y 3y
Sales (3.66%) 1.99% (0.99%)
Cash Flow (3.03%) 5.79% 17.54%
Earnings (6.85%) 0.00% 35.60%
Book Value (9.83%) 2.98% (0.97%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.63 Actual 0.72

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.53 0.50 Miss by 0.03
Q1 FY26 0.37 0.44 Beat by 0.07
Q2 FY26 0.57 0.63 Beat by 0.06
Q3 FY26 0.63 0.72 Beat by 0.09
Q4 FY26 0.60 — Reports 18 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.36 0.49 0.59 — —
’25 0.24 0.46 0.84 0.40 1.94
’24 0.05 (1.84) 0.23 0.36 (1.19)
’23 0.17 0.34 0.26 (1.50) (0.73)
’22 (0.25) 0.32 0.37 0.36 0.79
’21 0.21 0.41 0.36 0.55 1.53
’20 (0.23) (8.03) (0.49) (0.76) (9.55)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 476 488 501 — —
’25 458 469 493 494 1,914
’24 495 504 511 502 2,013
’23 491 501 507 496 1,995
’22 482 486 490 514 1,972
’21 447 473 493 499 1,911
’20 441 415 461 417 1,734
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (130) 125 117 — —
’25 (117) 137 137 114 271
’24 (125) 107 92 133 207
’23 (101) 89 80 69 137
’22 (97) 82 83 99 167
’21 (82) 54 61 44 77
’20 (142) 188 170 (12) 205
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (136) 124 113 — —
’25 (121) 133 132 109 253
’24 (131) 100 86 130 185
’23 (108) 81 71 60 104
’22 (105) 76 76 90 137
’21 (91) 69 51 41 69
’20 (152) 181 165 (19) 176
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 3,183 3,253 1,723 1,780 1,734 1,911 1,972 1,995 2,013 1,914 1,959 (5.5%) 1,967 2,011 2,078 +2.8%
Gross margin, % 32.47 28.27 29.31 28.27 25.91 26.85 23.68 21.13 22.57 25.80 26.12 (6.7) pt
EBT 514 386 166 59 7 135 81 (48) (101) 216 203 (9.2%)
EBT margin, % 16.14 11.85 9.65 3.30 0.41 7.08 4.13 (2.42) (5.03) 11.31 10.38 (4.8) pt
Net income 325 320 269 (1,498) (796) 131 66 (60) (99) 165 150 (7.2%)
Per share, $
Per share, $ Revenue 34.44 35.20 18.91 21.32 20.79 22.53 23.63 24.27 24.16 22.76 25.35 (4.5%)
Earnings 3.49 3.45 2.93 (17.94) (9.55) 1.53 0.79 (0.73) (1.19) 1.94 1.86 (6.3%)
Cash flow 4.80 5.53 3.44 4.28 2.45 0.90 2.00 1.67 2.48 3.22 2.94 (4.3%)
Capex (0.42) (0.28) (0.19) (0.23) (0.35) (0.09) (0.36) (0.41) (0.26) (0.22) (0.22) (7.1%)
Free cash flow 4.38 5.25 3.26 4.05 2.11 0.82 1.64 1.27 2.21 3.00 2.71 (4.1%)
Book value 29.87 33.18 33.89 17.95 8.97 10.57 10.68 10.33 9.18 10.30 10.99 (11.2%)
Shares, m 92 92 91 83 83 85 83 82 83 84 80 (1.0%)
Valuation, ×
Valuation, × P/E 19.13 15.87 11.26 0.00 0.00 17.78 18.78 0.00 0.00 11.03 17.08 9.4
P/S 1.94 1.56 1.74 1.00 1.20 1.21 0.64 0.39 0.54 0.94 1.25 1.1
P/B 2.24 1.65 0.97 1.54 2.79 2.57 1.41 0.91 1.43 2.08 2.89 1.8
EV/Sales 2.46 2.10 2.85 1.67 1.50 1.48 0.91 0.62 0.68 0.99 1.33 1.5
EV/FCF 19.35 14.10 16.57 11.48 14.81 40.83 13.13 11.79 7.38 7.51 12.42 15.7
Cash, $m
Cash, $m Operating cash flow 444 511 314 358 205 77 167 137 207 271 227 (5.3%)
Capex (39) (26) (17) (19) (29) (8) (30) (33) (22) (18) (17) (8.0%)
Free cash flow 405 485 297 338 176 69 137 104 185 253 210 (5.1%)
Balance, $m
Balance, $m Working capital 138 96 157 190 1,105 413 1 95 205 305 148 +9.2%
Net debt 1,639 1,782 1,907 1,566 516 518 548 456 269 98 152 (26.9%)
Shareholders’ equity 2,761 3,066 3,088 1,499 748 897 892 849 765 866 850 (12.1%)
Returns, %
Returns, % ROA 6.57 5.72 4.55 (29.71) (21.26) 4.31 2.62 (2.65) (4.53) 7.52 6.92 +1.0 pt
ROIC 8.12 5.86 3.11 3.50 4.85 8.97 7.50 0.35 (4.15) 13.55 13.27 +5.4 pt
ROE 12.50 11.00 8.73 (65.30) (70.90) 15.93 7.42 (6.94) (12.28) 20.28 17.25 +7.8 pt
People
People Employees 7,400 7,675 7,625 5,165 5,600 5,000 5,250 5,170 4,305 4,315 — (5.8%)
Revenue/emp, $m 0.43 0.42 0.23 0.34 0.31 0.38 0.38 0.39 0.47 0.44 — +0.3%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026

Pediatrix Medical Group, Inc. vs peers in Medical Care Facilities (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NHC National HealthCare Corporation $3.3B 28.2× 8.4× +6.61% (above 0%: growing) −65.61% (below 0%: shrinking) +75.52% (above 0%: growing) 100.00% 0.00% Compare
ACHC Acadia Healthcare Company, Inc. $3.2B — (loss-making) 34.4× +5.14% (above 0%: growing) −5.00% (below 0%: shrinking) +196.54% (above 0%: growing) 100.00% 0.00% Compare
SGRY Surgery Partners, Inc. $3.0B — (loss-making) — (loss-making) +2.75% (above 0%: growing) n/m −60.63% (below 0%: shrinking) 22.41% 12.78% Compare
AVAH Aveanna Healthcare Holdings Inc. $3.0B 10.5× 18.3× +13.73% (above 0%: growing) +46.15% (above 0%: growing) +57.89% (above 0%: growing) 32.59% 11.93% Compare
BKD Brookdale Senior Living Inc. $2.6B — (loss-making) 341× −11.61% (below 0%: shrinking) n/m +533.14% (above 0%: growing) 29.94% 11.86% Compare
GRDN Guardian Pharmacy Services, Inc. $2.5B 37.8× 33.3× −1.68% (below 0%: shrinking) +133.33% (above 0%: growing) +88.88% (above 0%: growing) 22.97% 6.75% Compare
MD Pediatrix Medical Group, Inc. $2.5B 17.1× 15.3× +1.72% (above 0%: growing) −27.61% (below 0%: shrinking) −14.41% (below 0%: shrinking) 27.98% 13.01%
ADUS Addus HomeCare Corporation $2.4B 21.1× 20.3× +7.02% (above 0%: growing) +24.19% (above 0%: growing) −17.07% (below 0%: shrinking) 32.08% 10.27% Compare
ASTH Astrana Health, Inc. $1.9B 46.8× 25.9× +48.52% (above 0%: growing) +110.53% (above 0%: growing) −67.74% (below 0%: shrinking) 10.70% 3.53% Compare
Median of peers $2.8B 28.2× 25.9× +5.88% +35.17% +66.70% 31.01% 8.51%

All 51 Medical Care Facilities stocks →

Pay and ownership Proxy statement filed 27 March 2026

Ownership

Directors and executive officers, together 1.80%
BlackRock, Inc. 15.10%
The Vanguard Group, Inc. 12.50%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Pediatrix Medical Group, Inc. (MD) Latest News

30 Oct

Impact 3 · · Moby

29 Oct

Impact 4 · · The Motley Fool transcript
Impact 4 · · Zacks
Impact 3 · · StockStory earnings
Impact 3 · · Associated Press
Impact 3 · · Business Wire

28 Oct

Impact 3 · · StockStory

23 Oct

Impact 4 ·
Impact 3 · · StockStory

20 Oct

Impact 3 · · Business Wire

14 Oct

Impact 3 · · StockStory

22 Sep

Impact 3 · · Zacks

21 Sep

Impact 3 · · Simply Wall St.

16 Sep

Impact 3 ·

26 Aug

Impact 3 ·

13 Aug

Impact 3 ·

11 Aug

Impact 3 · · The Motley Fool transcript

9 Aug

Impact 3 ·
Impact 3 ·

5 Aug

Impact 3 · · MarketBeat transcript

4 Aug

Impact 3 · · Moby
Impact 3 ·
Impact 3 ·
Impact 3 ·

16 Jul

Impact 3 ·

12 Jun

Impact 3 ·

27 May

Impact 3 · · Insider Monkey

17 May

Impact 3 · · Simply Wall St.

15 May

Impact 3 · · Zacks

14 May

Impact 3 · · Insider Monkey

MD metrics, ten years each

stockrow.com/MD · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com